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Background: Real-world data on patients’ and physicians’ values
related to the use of oral anticoagulant (OAC) therapy for stroke pre-
vention in patients with nonvalvular atrial ﬁbrillation are currently
lacking. We sought to assess the values, preferences, and experience
of patients who receive OAC therapy, and of physicians who prescribe
OAC therapy.
Methods: A national survey of randomly selected patients (n ¼ 266)
and physicians (n ¼ 178) was conducted between May and September
2014. Each was asked to evaluate the importance of individual OAC
attributes and identify which of 2 medication proﬁles they would prefer
(individual attributes were progressively modiﬁed to determine which
were the most valued and/or inﬂuenced treatment choice). Medication
adherence and prescription practice was also assessed.
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Introduction : Il y a actuellement penurie de donnees reelles, tant du
côte des medecins que des patients, en ce qui a trait au traitement
preventif de l’accident vasculaire cerebral (AVC) par un anticoagulant
oral chez les patients atteints de ﬁbrillation auriculaire non valvulaire.
C’est pourquoi nous avons entrepris de sonder les patients et les
medecins au sujet de leurs preferences et de leurs experiences à
l’egard de la prise ou de la prescription du medicament,
respectivement.
Methodes : Entre mai et septembre 2014, un sondage national a ete
mene auprès de patients (n ¼ 266) et de medecins (n ¼ 178)
selectionnes au hasard. On a demande aux participants d’evaluer
l’importance de diverses caracteristiques de ce type d’agent et de
choisir les deux proﬁls de medicament qu’ils preferaient (les ca-
racteristiques etaient modiﬁees de manière progressive en vue de
determiner lesquelles etaient les plus prisees et/ou inﬂuaient sur leAtrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia, and affects 5% of the population older than 65
years of age and 18% of those aged older than 85 years.1,2 A
core tenet of the management of AF is the prevention of AF-
related stroke and systemic embolism, a risk that is increased
ﬁvefold in patients with AF.1 For decades, oral vitamin K
antagonists (VKAs; eg, warfarin) have been widely used to
reduce the risk of stroke in patients with AF. Although
effective, VKAs have limitations.3 In recent years, severalnon-VKA oral anticoagulants (NOACs) have become avail-
able for clinical use. These agents (apixaban, dabigatran,
edoxaban, and rivaroxaban) have shown noninferiority to
warfarin for the prevention of stroke and systemic embolism
in patients with nonvalvular AF (NVAF), with generally
favourable risk-beneﬁt proﬁles in phase III randomized trials
as well as “real-world” studies.4-8
Current guidelines recommend the use of NOACs in
preference to VKAs for most patients with NVAF, with
consideration of individual needs and preferences.9,10 Unfor-
tunately, real-world data on patient and physician preferences
and values related to the use of oral anticoagulants (OACs) in
stroke prevention are lacking. Because an understanding of
patient attitudes toward, and preferences for, treatment for
chronic conditions is crucial for optimizing health care stra-
tegies, we undertook a study on the attitudes, values,n Cardiovascular Society. This is an open access article under the CC BY-NC-
and, to a lesser extent, efﬁcacy. When based solely on the basis of the
attribute proﬁle (blinded to the speciﬁc agent), physicians were more
likely to select apixaban (61%), whereas patients showed no signiﬁ-
cant preference among apixaban, rivaroxaban, and warfarin. Despite
this, 49% of physicians spontaneously stated rivaroxaban as their
preferred agent (vs 25% apixaban). Patients prescribed and taking
once daily medications (rivaroxaban or warfarin) showed better
compliance with their OAC therapy (approximately 30% of twice daily
medications being taken once daily, with signiﬁcantly more missed
doses compared with once daily medications).
Conclusions: Real-world prescriptions do not reﬂect reported values,
which suggests that other factors inﬂuence patient-physician decision-
making around OAC therapy. Data on self-reported adherence to OAC
therapy and discordance in the use of OACs from prescribed regimens
are concerning and warrant further investigation.
choix du traitement). Le sondage a aussi permis de veriﬁer l’obser-
vance du traitement et les habitudes de prescription du medicament.
Resultats : Les preferences differaient entre les patients et les
medecins, mais dans les deux cas elles etaient essentiellement axees
sur des caracteristiques liees à l’innocuite et, dans une moindre
mesure, à l’efﬁcacite. Lorsqu’ils se basaient uniquement sur le proﬁl
du medicament (le nom de l’agent n’etait pas devoile), les medecins
ont choisi le plus souvent l’apixaban (dans 61 % des cas), tandis que
les patients n’ont pas semble avoir de preference signiﬁcative pour un
agent ou pour un autre (apixaban, rivaroxaban et warfarine). En depit
de cela, 49 % des medecins ont spontanement cite le rivaroxaban à
titre de medicament de choix (vs l’apixaban dans 25 % des cas).
L’observance du traitement etait superieure chez les patients à qui on
avait prescrit un medicament à prise uniquotidienne (rivaroxaban ou
warfarine) puisque dans environ 30 % des cas, les medicaments à
prise biquotidienne n’etaient pris qu’une seule fois par jour, entraînant
ainsi un nombre signiﬁcativement plus eleve de doses manquees par
rapport aux medicaments à prise uniquotidienne.
Conclusions : Les ordonnances redigees en pratique clinique ne
reﬂètent pas les donnees recueillies lors du sondage, ce qui laisse
penser que d’autres facteurs inﬂuent sur la prise de decision des
medecins et des patients en matière d’anticoagulants oraux. De plus,
les donnees relatives à l’observance du traitement et à l’ecart entre la
prise reelle et les schemas posologiques des medicaments sont
inquietantes et justiﬁent la tenue d’etudes additionnelles.
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Volume 32 2016preferences, and experience of patients with NVAF who
receive OAC therapy for stroke prevention, as well as those of
physicians who prescribe OAC therapy.Methods
Study design and participants
A sample of NVAF patients who were prescribed OACs for
stroke prevention was surveyed between May and September
2014. Patients were recruited on a voluntary basis from: (1)
pharmacy dispensary counters (pharmacists were provided a
blinded invitation to hand out to any person who ﬁlled a
prescription for any of the target medications); (2) a syndi-
cated Canadian patient online panel (approximately 4500
Canadians who self-identiﬁed as undergoing regular medical
care, which was ﬁltered for individuals who self-identiﬁed as
receiving medical management for a heart condition. The
panel owner provided blinded invitations to these individuals,
and invited those currently taking 1 of the 4 target medica-
tions to participate); and (3) referrals from physicians associ-
ated with stroke management clinics in geographic regions not
sufﬁciently represented by participating pharmacies or the
syndicated panel (these physicians were invited by e-mail to
refer patients currently receiving 1 of the 4 target medications
to the study). All patients were screened to ensure that they
were currently taking an OAC (apixaban, dabigatran, rivar-
oxaban, or warfarin; edoxaban is not yet approved in Canada)
for stroke prevention in AF (SPAF). Maximum quotas were
set by medication use and geographic region (west: British
Columbia, Alberta, Saskatchewan, Manitoba; Central:
Ontario; East: Quebec, New Brunswick, Nova Scotia, Prince
Edward Island, Newfoundland).Over the same time period a sample of 175 physicians
from a pool of 13,876 physicians who prescribed OAC
therapy for SPAF were invited to participate in the survey.
Prerequisite for inclusion was on the basis of practice experi-
ence (they had practiced medicine for 2-35 years, and had
managed at least 10 patients in the past year with the speciﬁc
purpose of SPAF). Maximum quotas were set by medical
specialty and geographic region.Patient and physician surveys
The online survey conducted with patients sought to un-
derstand: (1) patient experiences with different OACs; (2)
their treatment history with respect to OAC therapy; (3) their
understanding of the treatment initiation process including
the type of information conveyed by the physician; and (4)
their compliance with OAC therapy. The survey required 35-
40 minutes to complete and is presented in the Supplemental
Methods.
The online survey for physicians sought to understand: (1)
their views of OAC therapy in SPAF; (2) the current and
future use of OAC for this indication; (3) their perceptions of
and experience with OAC and the treatment initiation pro-
cess; and (4) the information that is conveyed to patients. The
survey required 25-30 minutes to complete and is presented in
the Supplemental Methods.
Physicians and patients were asked to evaluate several
factors related to the use of NOACs, including: (1) the
effectiveness of the drug (expressed as an annual stroke-free
survival rate from the respective phase III studies); (2) the
requirement for regular blood testing; (3) the dosing regimen;
(4) the risk of a major bleeding event (expressed as rate per
year from the phase III studies); (5) the ability to rapidly
reverse anticoagulation in emergency circumstances; (6) the
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interactions with foods and/or other drugs (Supplemental
Table S1).
Conjoint analysis
A conjoint analysis of responses from physicians and pa-
tients was undertaken to establish which OAC attributes were
most valued and most likely to inﬂuence treatment choice.
For both respondent groups, we used the same design with
slightly different wording. We constructed a model with 2
three-level variables (bleeding rates and stroke-free survival)
and 5 two-level variables (requirement for blood testing,
dosing regimen, reversal, clinical experience, and drug/food
interaction) organized into 100 blocks of 12 questions each,
with each respondent answering a single block of 12 ques-
tions. The design tempered efﬁciency with some redundancy
to capture more information for respondents using non-
compensatory choice strategies. Each question forced re-
spondents to choose between 2 experimentally designed
medication proﬁles. At the conclusion of the conjoint exercise,
respondents selected among 3 OAC proﬁles in 1 scenario of
speciﬁc interest (see the Supplemental Methods). After the
preferred anticoagulant proﬁle had been chosen, respondents
were asked whether they would actually choose (for patients)
or prescribe (for physicians) that speciﬁc agent, with their
knowledge of the currently available OAC options.
Dosing and adherence to anticoagulant therapy
Patients were asked to specify which of the 4 approved
agents (apixaban, dabigatran, rivaroxaban, and warfarin) they
were taking for SPAF at the time of the survey, and how many
times per day they took the speciﬁed agent. Patients were
asked to provide information on how many doses of their
OAC medication they had missed in the week before the
survey (no missed doses was recorded as 0).
Data and statistical analysis
Continuous data are summarized by mean  standard
deviation or median and interquartile range, where appro-
priate. Categorical variables are expressed as frequency and
percentage.
For the patient and physician survey responses the un-
weighted data derived from rating scale, patient load, and
patient distribution type questions were summarized by mean
 standard deviation, or median  standard error as appro-
priate, and were analyzed, in most cases (where unequal var-
iances were assumed) using Student t tests for means. In some
cases (eg, comparison of physicians’ rating on different
products) a dependent paired/overlap test, which adopted the
Satterthwaite approximation, was used as the basis for
computation of the degrees of freedom for the 2-sample t test
when equality of variance was not assumed. In most cases in
which responses were provided as unpooled proportions,
analysis leveraged Z tests for proportions. In some cases (eg,
comparison of physicians’ rating on different products) a
dependent paired/overlap test was used. Signiﬁcance tests for
all survey-based statistics were 2-tailed tests at 2 conﬁdence
levels: 95% (P  0.05) and 90% (P  0.1).
For the conjoint analysis a disaggregate analysis via a hi-
erarchical Bayesian multinomial logit choice model waschosen. This analysis produced respondent-level utilities,
which were appropriately scaled to predict respondents’
choices in simulations, and improved the accuracy of simu-
lations by accounting for respondent heterogeneity. For
reporting purposes we rescaled the utilities with a trans-
formation known as zero-centred differences, to avoid
implicitly overweighting respondents who answered questions
more reliably. The respondent-level zero-centred differences
utilities are summarized with means, standard deviations, and
standard errors, the latter allowing signiﬁcance testing via
Student t tests. All tests were 2-sided and used a P value <
0.05 to determine statistical signiﬁcance.
The sample size for the survey (aggregate sample; patients
and prescribers) was calculated in an effort to achieve a 95%
conﬁdence interval, with a margin of error of 10%.
Role of the funding source
The study was sponsored by Bayer HealthCare. The design
of the study was conducted by the authors with data collection
and analysis conducted by a third party (Innomar Solutions).
All authors had involvement in the interpretation of data and
in the drafting and ﬁnalization of the report. D.P. and A.C.
are employees of Bayer Healthcare (the producer and dis-
tributer of rivaroxaban).Results
Patient survey
A total of 266 patients were surveyed. Patients were
recruited from Atlantic Canada and Quebec (20%), Ontario
(24%), Saskatchewan and Manitoba (19%), Alberta (18%),
and British Columbia (18%). More than 80% of the patients
were aged younger than 75 years. Apixaban and warfarin were
used more frequently in younger patients (18-64 years; 61%
and 70%, respectively), compared with rivaroxaban, which
was used relatively more frequently in older patients (65 years
of age and older; 60%). Dabigatran use did not differ between
age groups (51% used in those 18-64 years, and 49% in those
65 years and older).
Anticoagulant features, which were considered as most
important by patients, included: the efﬁcacy of the medication
for stroke prevention, the safety of the medication, and the
recommendation by their treating physician (average of  9.0
on a 10-point scale). Pharmacist recommendation, and
longstanding clinical experience were rated as less important
(average of < 7.5 on a 10-point scale).
When the responses were stratiﬁed according to current
drug use, the lack of blood testing was rated signiﬁcantly more
important by dabigatran- and rivaroxaban-treated patients
(8.7/10 each) compared with apixaban (7.6/10; P ¼ 0.027 vs
dabigatran, and P ¼ 0.041 vs rivaroxaban) and warfarin-
treated patients (7.0/10; P < 0.001 vs dabigatran, and P <
0.001 vs rivaroxaban); and once daily dosing was rated
signiﬁcantly more important among warfarin- (8.4/10) and
rivaroxaban- (8.5/10) treated patients compared with apix-
aban- (6.5/10; P ¼ 0.004 vs warfarin, and P ¼ 0.002 vs
rivaroxaban) and dabigatran- (5.8/10; P < 0.001 vs warfarin,
and P < 0.001 vs rivaroxaban) treated patients. The
remainder of the responses were consistent between groups.
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Figure 1. Results of the physician survey regarding oral anticoagulant
preferences and practices. (A) The physician stated preferred antico-
agulant proﬁle (on the basis of attribute proﬁle alone, with no knowl-
edge of the speciﬁc agent; note: attributes of dabigatran were not
included). (B) The physician stated spontaneously volunteered
preferred anticoagulant agent. (C) The relative proportion of agents
prescribed among the past 10 patients.
PaƟents Physicians 
InteracƟons with food/drug Risk of major bleeding 
Rapid reversal in emergency situaƟons InteracƟons with food/drug 
Clinical experience Requirement for regular blood tesƟng 
Requirement for regular blood tesƟng Rapid reversal in emergency situaƟons 
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Dosing frequency  Clinical experience 
Eﬃcacy (stroke-free survival) Eﬃcacy (stroke-free survival) 
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rated 
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Figure 2. Conjoint analysis. The relative importance of each attribute
(ie, the measure of how much effect an attribute has relative to the
other attributes), independently assessed by patients and physicians.
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Volume 32 2016Signiﬁcantly higher proportions of patients who received
rivaroxaban or dabigatran were taking other medications
(79% and 74%, respectively) compared with apixaban (58%;
P ¼ 0.101 vs dabigatran, and P ¼ 0.029 vs rivaroxaban) or
warfarin (53%; P ¼ 0.003 vs dabigatran, and P < 0.001 vs
rivaroxaban). However, for those who were taking other
medications, there was no difference in the average number of
additional medications (3.8 for warfarin, 4.2-4.4 for the
NOACs). Common concomitant medications included other
cardiovascular agents (81.7%) with b-blockers in 46.8%,
angiotensin-converting enzyme inhibitors in 33.2%, calcium
channel blockers in 22.5%, antiplatelet agents in 20.7%,
angiotensin receptor blockers in 16.7%, digoxin in 10.9%,
statins in 39.4%, and diuretics in 32.5% (Supplemental
Table S2). Concomitant proton pump inhibitors were used
in 24% of the rivaroxaban group compared with 16% for
apixaban and warfarin, and 18% for dabigatran. When pol-
ypharmacy was present, most (68%-74%) of the additional
medications were dosed once daily.
Physician survey
A total of 178 physicians, who collectively managed an
estimated 32,686 patients for SPAF were surveyed. Of these,
101 were general practitioners/family medicine specialists
(GP/FM), 41 were cardiologists, and 36 were internal medi-
cine specialists. There was approximately equal representation
from the Eastern, Central, and Western regions. Cardiologists
and internal medicine specialists managed three-quarters of all
patients (total 24,273 patients managed by specialists vs 8413
patients managed by GP/FM; mean of 315 patients per
specialist vs 83 patients managed by GP/FM). SPAF occupied
a major proportion of the respondents’ practice (16% overall;
11% of GP/FM, 22% of specialists), with most of this care
representing the ongoing follow-up of patients with AF who
were receiving OAC (69%; 73% for GP/FM and 68% for
specialists) rather than the management of newly diagnosed
AF.
Overall, rivaroxaban was identiﬁed as the preferred OAC
for SPAF (44%), followed by apixaban (23%), dabigatran
(12%), and warfarin (12%; P < 0.001; Fig. 1B). Nine percent
of physicians stated no preference with respect to anticoagu-
lant choice. The preference differed between GP/FM and
specialists with respect to apixaban (preferred by 16% of GP/
FM vs 31% of specialists; P ¼ 0.017) but not the other OACs
(dabigatran preferred by 11% vs 13%, P ¼ 0.671; rivaroxaban
preferred by 51% vs 36%, P ¼ 0.056; warfarin preferred by
15% vs 9%, P ¼ 0.232).
The attributes rated most important by physicians
included the efﬁcacy of the agent, the evidence base sup-
porting its use, and the safety proﬁle of the agent (average of
 9.0 on a 10-point scale). Pharmacist recommendation,
longstanding clinical experience, and the presence of an an-
tidote were rated as less important by physicians (average of <
7.5 on a 10-point scale).
Comparative analysis
Compared with GP/FM and patients, specialists rated the
importance of clinical data to support the use of an OAC
more highly (P ¼ 0.002) and were less likely to rate guideline
recommendation as inﬂuential (P < 0.001). Conversely,patients rated once-daily dosing as a signiﬁcantly more
important attribute compared with specialists (P < 0.001)
and rated the presence of an antidote or reversal agent as a
signiﬁcantly more important attribute compared with GP/FM
or specialists (P < 0.001). The lack of blood testing was
signiﬁcantly more highly rated by GP/FM compared with
specialists (P < 0.01).
Conjoint analysis
The order of OAC attributes in terms of importance
differed markedly between patients and physicians (Fig. 2).
Treatment initiation
Most of OAC initiations were by a GP/FM (41%) or
cardiologist (36%). The remainder were by an emergency
room physician (9%), internist (6%), neurologist (4%), or
hematologist (3%). For patients receiving apixaban, dabiga-
tran, and rivaroxaban, treatment was initiated for 70% at a
doctor’s ofﬁce or clinic outside of a hospital. Therapy was
started for warfarin patients either at a physician’s ofﬁce
(42%) or on admittance to a hospital (39%).
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SPAF. Half of all physicians recommended only what they
deemed the single most appropriate medication in the past 12
months (53% GP/FM; 46% specialists), whereas 46% pro-
vided several recommendations and discussed the beneﬁts and
drawbacks of each option with their patients (43% GP/FM,
51% specialists). Only 4% of patients requested a speciﬁc
medication and were prescribed accordingly by their
physician.
Among patients presented with several treatment options,
physicians reported nearly two-thirds made the ﬁnal decision
together with their patient (63% overall; 60% GP/FM, 68%
specialists). In 15% of cases the ﬁnal choice rested with the
treating physician (16% GP/FM, 13% specialists), and in
22% the patients made the ﬁnal choice (25% GP/FM, 20%
specialists). Conversely, patients reported that, when pre-
sented with several treatment options, 46% of all treatment
decisions were collaborative, 29% were made by the physician
alone, and 25% were made by the patient alone (Fig. 3).
Previous anticoagulation therapy
In patients who received warfarin, only 15% received
previous anticoagulant treatment. In patients who received a
NOAC, the prior use of warfarin was reported in 55% of
apixaban, 83% of dabigatran, and 48% of rivaroxaban. Pre-
vious aspirin use was observed in 25% who received apixaban,
30% who received dabigatran, and 32% who received rivar-
oxaban. Previous dabigatran use was observed in 35% of pa-
tients who received apixaban and 42% of patients who
received rivaroxaban. A physician’s recommendation was the
main reason for patients to switch to their current anticoag-
ulant medication (57% of respondents).
Dosing and adherence to therapy
Patients who were prescribed once-daily OACs reported
better compliance with their prescribed OAC therapy thanFigure 3. Perception regarding the degree of collaboration for oral
anticoagulant initiation. Among patients who were presented with
several treatment options by their physician the perception regarding
the individual making the ultimate treatment decision differed among
patients and physicians.those who were prescribed twice-daily OACs. Compared with
those who received apixaban or dabigatran, fewer patients who
received rivaroxaban or warfarin reported a missed dose in the
previous 7 days (Fig. 4A). The most common reason given for
missing a dose was forgetting to take the medication (58%
overall; 78% apixaban, 60% rivaroxaban, 53% dabigatran,
50% warfarin), or side effects (36%; no difference among
agents).
Patients were more likely to take the once-daily OACs at
the recommended dosing regimen. Six percent and 14% of
patients who received rivaroxaban and warfarin reported tak-
ing their OAC twice daily instead of once daily, 27% and
30% of patients who received dabigatran and apixaban took
their OAC once daily instead of their recommended twice-
daily dosing regimens (Fig. 4B; P < 0.001).
Patients who received rivaroxaban were less likely to
consider stopping treatment compared with those taking other
agents (8% for rivaroxaban vs 18% for warfarin, P ¼ 0.022;
18% for dabigatran, P ¼ 0.080; and 27% for apixaban, P ¼
0.022; Fig. 4C).Discussion
Current guidelines recommend the use of NOACs in
preference to VKAs for most patients with NVAF, with
consideration of individual needs and preferences.9,10 How-
ever, real-world data on patient attitudes toward, preferences
for, and values related to the use of NOACs in stroke pre-
vention are currently lacking. Because an understanding of the
attitudes, values, preferences, and experience of patients with
NVAF who receive OAC therapy is crucial for optimization of
treatment strategies, we undertook a study with the goal to
provide a picture of current treatment paradigms.
Within this context, our study showed the following: (1)
the preferences of patients and physicians in relation to OAC
therapy differ but are largely focused on characteristics related
to safety and, to a lesser extent, efﬁcacy (Fig. 2); (2) in the
conjoint analysis, physicians were more likely to select an
attribute proﬁle reﬂective of apixaban (61%), and patients
showed no signiﬁcant preference between apixaban, rivarox-
aban, and warfarin (Fig. 1A); (3) despite selection of an
attribute proﬁle compatible with apixaban, 49% of physicians
stated rivaroxaban was their preferred agent (vs 25% apixaban;
Fig. 1B), and were more likely to have recently prescribed
warfarin (36%), or rivaroxaban (31%) vs apixaban (15%;
Fig. 1C); and (4) although dosing frequency was not rated as a
highly desirable attribute, patients who were prescribed once
daily medications (rivaroxaban or warfarin) showed better
compliance with their OAC therapy (almost one-third of
twice daily prescribed medications were being taken once daily
and signiﬁcantly more missed doses of the twice daily pre-
scribed medications were reported) and were less likely to
consider stopping their OAC therapy (Fig. 4C).
The discrepancy between the reported patient and physi-
cian preferences, and the real world application (ie, pre-
scriptions) likely reﬂects a combination of factors. First,
despite being a highly rated attribute, the inﬂuence of efﬁcacy
on decision-making was marginal in the conjoint analysis,
which suggested that patient and physician decision-making
was more reliant on other differentiating features, such as
bleeding, reversal, and food-drug interactions. Most likely this
Figure 4. Therapy adherence. (A) Proportion of patients with missed doses of their anticoagulant in the past week, stratiﬁed according to agent and
number of missed doses. (B) Proportion of patients who are currently using the wrong dosing frequency of their anticoagulant. (C) Proportion of
patients who had considered stopping their anticoagulant therapy within the past year. OAC, oral anticoagulant.
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Volume 32 2016reﬂects the excellent efﬁcacy of all the agents (eg, 1-year
freedom from stroke between 97.9% and 98.1%).4-6 Second,
although “drug cost” and “drug coverage” were not ranked
highly as attributes in the preferences survey, it is highly likely
that the medication costs inﬂuenced some of the discrepancy.
In most Canadian jurisdictions, a trial of warfarin is a neces-
sary prerequisite before NOACs are covered by provincial
agencies or extended health providers. This likely explains the
disproportionate amount of prescriptions for warfarin relative
to the other agents. It is possible that, in the absence of
ﬁnancial barriers, the prescription practices might have
differed. Last, the timing of regulatory approval differed
among NOACs (dabigatran in October 2010, rivaroxaban in
January 2012, and apixaban in December 2012). Although
this would not be expected to inﬂuence the subjective
weighting of individual or collective attribute importance, it
might have inﬂuenced patient and physician familiarity,
which could explain some of the differences observed between
the physician-stated “preferred” OAC agent, and the agent
that was ultimately prescribed. As such it is possible that some
physicians were not aware of which of the currently available
NOACs has the attributes that they prefer.
Moreover, although dosing schedule was variably ranked in
the attribute analysis, clear differences in adherence and
persistence were observed in the real-world analysis. Although
a preference toward once daily dosing convenience,11-13 as
well as an improved long-term treatment adherence isknown,14,15 the self-reported data on divergence from the
prescribed regimens (up to a third of twice daily prescribed
medications being taken once daily) and the frequency of
missed doses are concerning and warrant further investigation.
Although we were unable to consider the consequences of
missed dosages in our survey, it is well known that non-
adherence is associated with ‘adverse’ clinical outcomes.16
These data highlight the need for improved patient educa-
tion, and knowledge translation between physicians and
patients.
The current study has several limitations. First, the study
consisted of a strong primary sample size (266 patients and
178 physicians) but had limited scope for subanalyses or
stratiﬁcation according to patient characteristics such as stroke
risk. Most patients (69%) in this study were receiving
“maintenance” OAC therapy and were not patients with
newly diagnosed AF; therefore, it is possible that their previ-
ous experience with adverse events associated with AF (eg,
stroke) or antithrombotic treatment (eg, bleeding) could have
inﬂuenced their responses. The patients and physicians were
recruited using an opportunistic sampling methodology, and
as such, a potential bias for participation might exist due to
several motivating factors including: patient desire to meet the
request of their health care provider (physician or pharmacist),
physician desire to contribute to research, and ﬁnancial
motivation (honoraria were paid for completed surveys). One
must also consider the effect of a positive response bias for
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response they believed was “appropriate” rather than their
actual behaviour, out of concern that their responses might
somehow affect their level of care. However, we attempted to
minimize the effect of this through question sequence
randomization, response option randomization within a given
question, as well as internal redundancy and/or validation
within the questionnaire and conjoint designs. Last, the pa-
tients who participated in the survey were relatively young (>
80% were younger than 75 years of age), with signiﬁcant age
differences noted among the patients who received different
anticoagulants. It is possible that patient age might have
inﬂuenced relative attribute importance.
In conclusion, patients and physicians value medications
for stroke prevention that are efﬁcacious and safe, although
the ideal characteristics differ between patients and physicians,
and within physician groups. However, real-world pre-
scriptions do not necessarily reﬂect these values, which sug-
gests other factors inﬂuence patient-physician decision-
making around OAC therapy. Data from larger, global, real-
world studies will provide further insight into the current
treatment patterns, patient adherence, and long-term clinical
outcomes in patients who receive NOACs.Funding Sources
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